Twist Bioscience Corporation
Twist Bioscience Corporation（TWST）股东结构
基于 13F 申报与流通股数据，展示机构、内部人与公众持股结构；下方为前十大机构、机构动向与内部人交易。
SEC 13F · FMP · TWST · 截至 2025年9月30日
股东结构概览
242
机构持有人数
▼ 6 vs Q2
$2.08B
机构持仓总市值
▼ $540.64M vs Q2
62.27M
总流通股
freeFloat 95.69%
73.79M
13F 申报持股数
▲ 2.65M vs Q2
机构持仓% = 13F 持股数 ÷ 总流通股。内部人% = 100 − 自由流通率。散户% = 自由流通率 − 机构%。数据来源：FMP /symbol-positions-summary + /shares-float + SEC EDGAR。
前10大机构持仓
TWST 最大股东 · 机构持仓
Q3 2025 · SEC 13F
显示前 10 家
| 机构 | 持股数 | 占比 | 权重 | 市值 | 申报日 | 变动 |
|---|---|---|---|---|---|---|
ARK INVESTMENT MANAGEMENT LLC biological products, (no diagnostic substances) | 6.73M | 11.21% | 11.21% | $189.29B | Nov 12, 2025 | ▲ 326.4K |
ARTISAN PARTNERS LIMITED PARTNERSHIP biological products, (no diagnostic substances) | 6.41M | 10.69% | 10.69% | $180.40B | Nov 12, 2025 | ▲ 1.35M |
BLACKROCK, INC. biological products, (no diagnostic substances) | 6.18M | 10.30% | 10.30% | $173.86B | Nov 12, 2025 | ▼ 98.1K |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 5.77M | 9.61% | 9.61% | $162.32B | Nov 7, 2025 | ▼ 63.2K |
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC biological products, (no diagnostic substances) | 4.14M | 6.90% | 6.90% | $116.56B | Nov 12, 2025 | ▲ 235.7K |
EDGEPOINT INVESTMENT GROUP INC. biological products, (no diagnostic substances) | 4.08M | 6.80% | 6.80% | $114.88B | Nov 14, 2025 | ▲ 1.70M |
STATE STREET CORP biological products, (no diagnostic substances) | 3.09M | 5.15% | 5.15% | $86.93B | Nov 14, 2025 | ▲ 588.1K |
SUMITOMO MITSUI TRUST HOLDINGS, INC. biological products, (no diagnostic substances) | 2.12M | 3.53% | 3.53% | $59.66B | Oct 27, 2025 | ▼ 179.2K |
NIKKO ASSET MANAGEMENT AMERICAS, INC. biological products, (no diagnostic substances) | 2.12M | 3.53% | 3.53% | $59.64B | Nov 12, 2025 | ▼ 179.2K |
SOLEUS CAPITAL MANAGEMENT, L.P. biological products, (no diagnostic substances) | 1.87M | 3.11% | 3.11% | $52.52B | Nov 14, 2025 | ▲ 1.51M |
数据来源：SEC 13F 申报文件。变动标识：isNew / isSoldOut / changeInSharesNumber。
机构仓位变动
Q3 2025 对比上季度
Q3 2025
33
增持
+9.91M 股0
新建仓
首次建仓16
减持
−4.20M 股0
清仓
完全退出净股数变化（前50家）
+5.71M
+9.91M / −4.20M
净新增持仓人
+17
新建 0 个 / 退出 0 个
基于前50家最大机构持仓统计，全市场实际数量可能不同。
内幕交易买卖情绪
TWST 内幕交易记录
数据来源：SEC Form 4
近期内部人员以卖出为主。 卖出可能源于预定的 10b5-1 计划，不代表负面展望。
10
买入笔数
27
卖出笔数
0.37
买卖比
$0M
卖出总金额
最近内幕交易记录
最近10条 · 仅普通股
| 姓名 · 职位 | 日期 | 类型 | 股数 | 价格 | 金额 | 交易后持股 | 申报 |
|---|---|---|---|---|---|---|---|
Cho Dennis See Remarks | May 29, 2026 | Sale | 14,205 | $69.75 | $990.8K | 120.1K | Form 4 ↗ |
Laponis Adam Chief Financial Officer | May 29, 2026 | Sale | 4,000 | $70.00 | $280.0K | 112.7K | Form 4 ↗ |
Leproust Emily M. Chief Executive Officer | May 28, 2026 | Sale | 1,482 | $65.33 | $96.8K | 861.9K | Form 4 ↗ |
Leproust Emily M. Chief Executive Officer | May 28, 2026 | Sale | 900 | $66.85 | $60.2K | 861.0K | Form 4 ↗ |
Leproust Emily M. Chief Executive Officer | May 28, 2026 | Sale | 7,623 | $67.95 | $518.0K | 853.3K | Form 4 ↗ |
Leproust Emily M. Chief Executive Officer | May 28, 2026 | Sale | 6,465 | $68.61 | $443.6K | 846.9K | Form 4 ↗ |
Starovasnik Melissa A. director | May 28, 2026 | Sale | 2,500 | $68.00 | $170.0K | 22.2K | Form 4 ↗ |
Starovasnik Melissa A. director | May 26, 2026 | Sale | 500 | $61.04 | $30.5K | 24.7K | Form 4 ↗ |
Leproust Emily M. Chief Executive Officer | May 27, 2026 | Sale | 23,752 | $65.24 | $1.55M | 848.1K | Form 4 ↗ |
Leproust Emily M. Chief Executive Officer | May 26, 2026 | Sale | 24,282 | $65.08 | $1.58M | 846.9K | Form 4 ↗ |
数据来源：SEC Form 4。买卖方向：acquisitionOrDisposition A=买入，D=卖出。已排除 RSU 归属（M-Exempt）。
关于机构与内部人持股结构
Twist Bioscience Corporation（TWST）主要由机构投资者持有，机构持股比例约为 100.0%。公司内部人员持股约 4.31%，散户及公众持股约占剩余的 0.00%。
Twist Bioscience Corporation 最大机构股东为 ARK INVESTMENT MANAGEMENT LLC，截至 September 30, 2025 持有约 6.73 million 股，占总流通股的 11.21%。
目前共有 242 家机构持有 TWST 股票，合计持仓市值约 $2.08 billion，数据来源为最新 SEC 13F 申报。
常见问题
TWST ownershipTwist Bioscience Corporation（TWST）主要由机构投资者持有，机构持股约 100.0%。最大股东为 ARK INVESTMENT MANAGEMENT LLC，持股比例 11.21%。内部人员持股约 4.31%。数据来源 SEC Form 13F，截至 September 30, 2025。